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Background Little is known about the impact of psychological risk factors on cardiac prognosis in the drug-eluting stent
era. We examined whether the distressed personality (Type D) moderates the effect of percutaneous coronary intervention
with sirolimus-eluting stent implantation on adverse clinical events at 2-year follow-up. Type D is an emerging risk factor in
patients with cardiovascular disease.
Design Prospective follow-up study.
Methods Three hundred and fifty-eight patients with ischemic heart disease, who consecutively underwent percutaneous
coronary intervention with sirolimus-eluting stent as part of the Rapamycin-Eluting Stent Evaluated At Rotterdam
Cardiology Hospital registry, completed the Type D Scale (DS14) post-percutaneous coronary intervention (PCI). The end-
point was a composite of death and non-fatal myocardial infarction 2 years after PCI.
Results At follow-up, there were 22 events (12 deaths and 11 myocardial infarctions). Type D patients had a greater than
two-fold risk of an event at follow-up compared with non-Type D patients (10.4 vs. 4.4%, P = 0.031). In multivariable analysis,
Type D remained an independent predictor of adverse outcome (hazard ratio: 2.61; 95% confidence interval: 1.12–6.09;
P = 0.027) adjusting for sex, age, and history of coronary artery disease, multivessel disease, diabetes, hypercholestero-
lemia, hypertension, renal impairment and smoking. Previous cardiac history was also an independent predictor of death or
myocardial infarction (hazard ratio: 2.83; 95% confidence interval: 1.00–7.96; P = 0.049).
Conclusions Type D personality moderated the effect of percutaneous coronary intervention on hard clinical events
despite treatment with the latest innovation in interventional cardiology. The inclusion of psychological risk factors in
general and personality factors in particular may optimize risk stratification in the drug-eluting stent era. Eur J Cardiovasc
Prev Rehabil 14:135–140 c 2007 The European Society of Cardiology
European Journal of Cardiovascular Prevention and Rehabilitation 2007, 14:135–140
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Introduction
The drug-eluting stent represents a breakthrough in the
25-year history of interventional cardiology. Drug-eluting
stent implantation has to a large extent done away with
restenosis, the ‘Achilles heel’ of percutaneous coronary
intervention (PCI) and thereby the need for repeat
revascularization [1–3]. In the future, drug-eluting stent
implantation is likely to become the treatment of choice.
In the US, it has been estimated that 80% of eligible
patients would be treated with drug-eluting stents at
the end of 2003 [4]. In randomized, controlled trials,
drug-eluting stents have not been shown to confer any
benefits on the incidence of death or myocardial
infarction (MI) [5]. This has also been confirmed in
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registries of unselected patients, who represent the ‘real
world’ of interventional cardiology [6].
In the drug-eluting stent era, there is therefore still a
need to identify risk factors in order to improve risk
stratification in patients treated with this innovative
technique. The study of non-traditional risk factors, such
as psychosocial factors, in addition to the traditional risk
factors may help identify subgroups of patients at risk of
adverse prognosis. The inclusion of psychosocial risk
factors in research and clinical practice has also been
advocated in the recent guidelines of the European
Society of Cardiology on the prevention of coronary artery
disease (CAD) [7] and elsewhere [8]. Moreover, in the
predrug-eluting stent era the majority of studies on the
impact of psychosocial factors on cardiac prognosis have
been conducted in post-MI patients. Less emphasis has
been given post coronary artery bypass graft surgery
(CABG) patients [9] and even less focus on post-PCI
patients [10].
The distressed personality type (Type D), an emerging
risk factor, has been shown to contribute to the pathogen-
esis of CAD [11–14]. Type D has also been associated with
increased distress and impaired health status [15,16]. Type
D refers to individuals who tend to experience increased
negative emotions and who do not express these emotions
in social interactions owing to fear of how others may react
[14]. Due to the inclusion of the social inhibition
component, Type D is more than just negative affect,
such as depression, in that the construct also assesses how
patients deal with these negative emotions. It is only
patients who score high on both negative affectivity and
social inhibition that are at increased risk, with social
inhibition modulating the effect of negative emotions on
clinical outcome [17]. Studies in the pre drug-eluting
stent era have shown that the prognostic value of Type D
personality is as powerful as left ventricular dysfunction,
and that the impact of Type D on prognosis is independent
of disease severity [11–14] and short-term changes in
mood, such as depression and anxiety [12,13]. Initial
analyses from the Rapamycin-Eluting Stent Evaluated At
Rotterdam Cardiology Hospital (RESEARCH) registry
suggested that Type D personality may be a risk factor
for adverse clinical events 15 months post-PCI (i.e. 9
months following assessment of Type D) [18]. Given the
relatively short-term follow-up, however, we included
patients treated with sirolimus-eluting stent (SES) as well
as bare metal stent implantation, and did not examine
whether Type D moderates the effect of PCI on prognosis
in the drug-eluting stent era, that is in patients treated
exclusively with SES [18].
In this study, we therefore investigated whether Type D
personality predicts the occurrence of adverse clinical
events at 2 years in post-PCI patients treated exclusively
with SES.
Methods
Patient population and study design
Unselected consecutive patients with ischemic heart
disease undergoing PCI with SES (Cypher; Johnson &
Johnson-Cordis unit, Cordis Europa NV, Roden, The
Netherlands), who participated in the RESEARCH
registry between April and October 2002, qualified for
inclusion in the current study. Details of the RESEARCH
registry have been published elsewhere [19]. The registry
was designed to reflect the ‘real world’ of interventional
cardiology for which reason all patients were eligible for
enrolment regardless of anatomical or clinical presenta-
tion. In brief, the purpose of the registry was to
investigate the impact of SES implantation on the clinical
outcomes of patients treated with PCI.
At 6 months, all living patients (n = 549) were contacted
by letter and asked to fill in a psychological questionnaire
(see Materials), of which 358 (65%) returned the
questionnaire. All patients were prospectively followed-
up for clinical adverse events.
Apart from responders being older than non-responders
(62 vs. 60 years; P < 0.05), we found no other statistically
significant differences between the two groups on
demographic and clinical characteristics at the time of
administration of the psychological questionnaire.
The registry was approved by the hospital ethics
committee, and it was carried out in accordance with
the Helsinki Declaration. Every patient provided written
informed consent.
Materials
Demographic and clinical variables
Demographic variables included sex and age. Information
on clinical variables (MI, previous PCI, previous CABG,
multivessel disease, hypertension, hypercholesterolemia,
diabetes mellitus, renal impairment, and smoking status)
was obtained from the patients’ medical records.
Type D personality
Type D personality was assessed with the Type D Scale
(DS14), a 14-item scale rated on a 5-point Likert scale
from 0 (false) to 4 (true) [20]. The scale consists of two
subscales, that is, the stable traits of negative affectivity
(e.g. ‘I am often in a bad mood’) and social inhibition
(e.g. ‘I am a ‘closed’ person’). A high score on both compo-
nents (using a standard cut-off score Z 10) denotes those
with a Type D personality. Type D defines individuals
who tend to experience increased negative emotions and
who do not express these emotions in social interactions.
The DS14 has adequate reliability with Cronbach’s
a= 0.88 and a= 0.86 for the negative affectivity and the
social inhibition subscales, respectively [20]. The test–
retest reliability r = 0.72/0.82 for the negative affectivity
136 European Journal of Cardiovascular Prevention and Rehabilitation 2007, Vol 14 No 1
Copyright © European Society of Cardiology. Unauthorized reproduction of this article is prohibited.
and social inhibition subscales indicates that the two
traits reflect stable tendencies to experience negative
emotions paired with the tendency not to express these
emotions across time and situations [20]. As described
elsewhere, the DS14 was administered 6 months post-
PCI [18].
Clinical endpoint and definitions
The endpoint was defined as the occurrence of a
composite of death (all-cause) or non-fatal MI at 2 years
after PCI (i.e. 18 months after assessment of Type D
personality). MI was diagnosed by a rise in the creatine
kinase-MB level to more than three times the upper
normal limit [21]. Deaths (n = 14) occurring between the
index event and administration of the psychological
questionnaire were excluded from statistical analyses.
MIs that occurred before the administration of the
questionnaire were included as prior MIs in analyses.
Reported baseline characteristics are characteristics at
the time of administration of the DS14.
Statistical analysis
Discrete variables were compared with the w2 test
(Fisher’s exact test when appropriate) and continuous
variables with the Student’s t-test. The cumulative
adverse event rate at 2-year follow-up was calculated
according to the Kaplan–Meier method. The log-rank test
was used to compare the event rate between Type D and
non-Type D patients. Univariable and multivariable Cox
proportional hazards regression analyses were performed
to investigate the impact of Type D personality on the
endpoint at 2-year follow-up. In multivariable analysis,
we adjusted for sex, age Z 60 history of CAD (defined as
MI, PCI, or CABG before the index event), multivessel
disease, diabetes, hypercholesterolemia, hypertension,
renal impairment, and smoking. All statistical tests were
two-tailed. P < 0.05 was used for all tests to indicate
statistical significance. Hazard ratios (HR) with 95%
confidence intervals (CI) are reported. All statistical
analyses were performed using SPPS for Windows version
12.0.1 (SPSS Inc., Chicago, Illinois, USA).
Results
Baseline characteristics of patients stratified by personality
type are shown in Table 1. Of the 358 patients, 106 (30%)
had a Type D personality, which is consistent with the
prevalence found in other studies of cardiac patients
[11–13]. The only significant difference on baseline
characteristics was found on smoking with Type D patients
being more likely to smoke than non-Type D patients.
Between baseline and 2 years follow-up (mean = 24
months; median = 25 months), 23 events (12 deaths
and 11 MIs) had occurred. One patient had suffered both
events reducing the total number of events to 22 for
regression analyses.
At follow-up, patients with a Type D personality had
experienced significantly more events than non-Type D
patients [11/106 (10.4%) vs. 11/252 (4.4%), P = 0.031];
Type D patients had a greater than two-fold (HR: 2.51;
95% CI: 1.09–5.82) risk of death or MI (Fig. 1).
In multivariable analysis, Type D remained an indepen-
dent predictor of adverse outcome (HR: 2.61; 95% CI:
1.12–6.09), adjusting for sex, age, and clinical risk factors
(Table 2). Previous cardiac history was also an indepen-
dent predictor of death or MI (HR: 2.83; 95% CI:
1.00–7.96) (Table 2).
Discussion
This is the first study to examine whether psychological
risk factors in general and Type D personality in particular
Table 1 Baseline characteristics (6 months after PCI)
Type D
(n = 106) n (%)
Non-Type D
(n = 252) n (%)
P
Demographics
Female sex 33 (31) 70 (28) 0.522
Age (years) mean (SD) 61 (11) 63 (10) 0.125
Clinical risk factors
Previous MIa 38 (36) 79 (31) 0.392
Previous PCI 32 (30) 73 (29) 0.817
Previous CABG 10 (9) 36 (14) 0.210
Multivessel disease 59 (56) 133 (53) 0.618
Hypertensionb 44 (42) 105 (42) 0.978
Hypercholesterolemiac 84 (79) 199 (79) 0.953
Diabetes mellitusb 19 (18) 39 (16) 0.566
Renal impairmentd 21 (20) 52 (21) 0.865
Smokinge 37 (35) 58 (23) 0.020
Previous CABG, coronary artery bypass surgery before index event; previous MI,
myocardial infarction before index event; previous PCI, percutaneous coronary
intervention before index event. aOn the basis of the judgement of the treating
physician. bPresent if being treated for the condition. cTotal cholesterol levels
> 240 mg/dl or on lipid-lowering medication. dIndicated by creatinine clearance
























HR: 2.51 (95% CI: 1.09–5.82)
Kaplan–Meier curves for 2-year cumulative risk of death or non-fatal
myocardial infarction stratified by Type D personality (unadjusted
analyses). Time refers to time since sirolimus-eluting stent (SES)
implantation. CI, confidence interval; HR, hazard ratio.
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moderate the effect of PCI on clinical events in patients
treated exclusively with drug-eluting stents. In post-PCI
patients treated with SES, we found that Type D was
associated with a greater than two-fold risk of mortality or
non-fatal MI, adjusting all demographic and clinical risk
factors. This shows that Type D patients do not benefit
from SES implantation on par with non-Type D patients.
The findings of the current study suggest that Type D
moderates the effect of PCI with SES on hard clinical
events. In the pre drug-eluting stent era, Type D has also
been shown to moderate the effects of treatment in
patients with established CAD [22], and to be associated
with adverse prognosis [11–14]. Similar results were
found in a mixed group of patients treated with SES or
bare metal stent implantation [18].
Several pathways are present through which Type D
personality may exert an adverse impact on prognosis.
Type D patients may be less likely to engage in optimal
health-related behaviours, such as adhering to dietary
restrictions, exercising and quitting smoking. Our data
support this notion, as Type D patients were more likely
to smoke than non-Type D patients. Nevertheless, the
effect of Type D remained when adjusting for smoking in
multivariable analysis. Unfortunately, no other health-
related behaviours were assessed in the study.
Inflammation may provide another mechanism. Athero-
sclerosis is increasingly being recognized as an inflamma-
tory process [23], and in turn inflammatory markers such
as C-reactive protein [24] and white blood cell count [25]
have been associated with an increased risk of mortality
post-PCI. Studies indicate that an inflammatory response
follows subsequent to stent deployment owing to injury
to the vessel wall [26], but also that inflammatory status
before PCI may be an important determinant of clinical
outcome after PCI [26]. In patients with chronic heart
failure, Type D has been associated with increased levels
of TNF-a and TNF-a-soluble receptors 1 and 2 [27],
which are important predictors of mortality in chronic
heart failure [28]. It is possible that Type D patients
differ in their inflammatory status before PCI and their
response after PCI compared with non-Type D patients,
in turn rendering them at increased risk of adverse
clinical outcome.
The findings of the current study have implications for
research and clinical practice, and underscore the
importance of including psychological risk factors in
general and personality factors in particular. This was also
advocated in the recent guidelines of the European
Society of Cardiology for the prevention of cardiovascular
disease [7]. The Type D Scale has been recommended as
one of the screening tools to use in clinical practice [8],
and the scale is included in the Euro Cardio-QoL Project,
which has an objective of developing a core heart
disease health-related quality of life questionnaire [29].
The extent to which Type D moderates the effect of
cardiac rehabilitation deserves further attention.
Although it is speculative, the results of the current
study and previous studies showing that Type D
moderates the effect of medical treatment [18,22]
suggest that Type D patients may also be less likely to
benefit from standard cardiac rehabilitation programmes,
probably owing to their tendency not to express negative
emotions when together with others. These patients may
be quieter in a rehabilitation setting and less likely to
share information with an emotional content. Hence,
Type D patients may need more encouragement to talk
about their feelings than non-Type D patients, although a
prerequisite for sharing their emotions will be that they
experience the rehabilitation context as sufficiently safe
and pleasant. Individual therapy sessions may also be
helpful for Type D patients, as a one-to-one relationship
is less threatening to them than a group setting.
Prospective studies are now warranted that investigate
the extent to which Type D also moderates the effect of
cardiac rehabilitation on prognosis, and which mechan-
isms may be responsible for the adverse effect of Type D
on cardiac prognosis, be they behavioural, physiological or
a combination thereof. Knowledge of these mechanisms is
likely to point to targets for intervention, such that Type
D patients may benefit from treatment, including cardiac
rehabilitation, on par with non-Type D patients and have
a better prognosis.
The results of this study should be interpreted with some
caution. First, Type D personality was not assessed at the
time of the index event, as described previously [18].
This may have biased our results, as patients who died
between 0 and 6 months after PCI did not have the
opportunity to fill in the psychological questionnaire.
This is, however, likely to have led to an underestimation
of the impact of Type D rather than an inflation given
Table 2 Predictors of death or MI at 2-year follow-up (adjusted
analysis)a
Predictor variables HR (95% CI) P
Type D 2.61 (1.12–6.09) 0.027*
Female sex 0.62 (0.22–1.79) 0.379
Age Z60 years 1.12 (0.43–2.94) 0.814
CAD historyb 2.83 (1.00–7.96) 0.049*
Multi-vessel disease 1.95 (0.74–5.13) 0.179
Diabetesc 2.40 (0.92–6.23) 0.072
Hypercholesterolemiad 0.94 (0.31–2.84) 0.907
Hypertensionc 0.88 (0.36–2.15) 0.772
Renal impairmente 2.05 (0.77–5.44) 0.150
Smokingf 2.07 (0.78–5.46) 0.142
CABG, coronary artery bypass surgery; CAD, coronary artery disease; CI;
confidence interval; HR, hazard ratio; MI, myocardial infarction. aEnter procedure.
bMI, PCI or CABG before the index event. cPresent if being treated for the
condition. dTotal cholesterol levels > 240 mg/dl or on lipid-lowering medication.
eIndicated by creatinine clearance < 61 ml/min. fOn the basis of self-report.
*P < 0.05.
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that Type D patients are at increased risk of adverse
prognosis. Second, the results may not be generalizable
to the total sample given that the response rate was 65%
and that responders and non-responders differed on
one baseline characteristic (i.e. age). Third, we had no
information on left ventricular dysfunction, which is an
established risk factor for adverse prognosis. In multi-
variable analysis, however, we did control for multivessel
disease, an objective measure of disease severity. Finally,
we had no information on the use of psychotropic
medication, participation in cardiac rehabilitation, and
health-related behaviours, except for smoking, which may
have influenced the endpoint. Despite these limitations,
an advantage of the current study is that the results
reflect the ‘real world’ of interventional cardiology, as the
sample consisted of unselected patients. Later analyses of
the RESEARCH registry population have shown that 68%
of the patients would not have been included in clinical
trials owing to their more complex clinical profile [30].
In conclusion, this study showed that Type D personality
moderates the effect of PCI on clinical outcome 2 years
after the index event despite treatment with the latest
innovation in interventional cardiology. This shows that
Type D is also a risk factor in the drug-eluting stent era.
The inclusion of psychological risk factors in general,
and personality factors in particular may optimize risk
stratification in clinical practice in the drug-eluting
stent era.
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